291 related articles for article (PubMed ID: 34587768)
21. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
22. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
Mansilla-Polo M; Escutia-Muñoz B; Botella-Estrada R
Actas Dermosifiliogr; 2023 Oct; 114(9):T772-T783. PubMed ID: 37541580
[TBL] [Abstract][Full Text] [Related]
23. Narrative Review and Update on Biologic and Small Molecule Drugs for Hidradenitis Suppurativa: An Entity With a Promising Future.
Mansilla-Polo M; Escutia-Muñoz B; Botella-Estrada R
Actas Dermosifiliogr; 2023 Oct; 114(9):772-783. PubMed ID: 37211274
[TBL] [Abstract][Full Text] [Related]
24. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
[TBL] [Abstract][Full Text] [Related]
25. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.
Guermazi D; Shah A; Yumeen S; Saliba E
Arch Dermatol Res; 2024 May; 316(6):259. PubMed ID: 38795234
[TBL] [Abstract][Full Text] [Related]
26. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
Bechara FG; Podda M; Prens EP; Horváth B; Giamarellos-Bourboulis EJ; Alavi A; Szepietowski JC; Kirby J; Geng Z; Jean C; Jemec GBE; Zouboulis CC
JAMA Surg; 2021 Nov; 156(11):1001-1009. PubMed ID: 34406349
[TBL] [Abstract][Full Text] [Related]
28. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
[No Abstract] [Full Text] [Related]
29. Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.
Huang CH; Huang IH; Tai CC; Chi CC
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740325
[TBL] [Abstract][Full Text] [Related]
30. Update on Hidradenitis Suppurative (Part II): Treatment.
Martorell A; García FJ; Jiménez-Gallo D; Pascual JC; Pereyra-Rodríguez J; Salgado L; Villarrasa E
Actas Dermosifiliogr; 2015 Nov; 106(9):716-24. PubMed ID: 26277040
[TBL] [Abstract][Full Text] [Related]
31. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
Zouboulis CC
Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
34. Secukinumab in the treatment of hidradenitis suppurativa.
Snyder CL; Gibson RS; Porter ML; Kimball AB
Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
[TBL] [Abstract][Full Text] [Related]
35. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
36. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
Markota Čagalj A; Marinović B; Bukvić Mokos Z
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
[TBL] [Abstract][Full Text] [Related]
37. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
38. Shorter time to initiation of biologic therapy in the setting of a hidradenitis suppurativa specialty clinic.
Kearney N; O'Donohoe S; Hughes R; Kirby B
Clin Exp Dermatol; 2023 Sep; 48(10):1149-1151. PubMed ID: 37256275
[TBL] [Abstract][Full Text] [Related]
39. Biologic Treatment for Hidradenitis Suppurativa.
Flood KS; Porter ML; Kimball AB
Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
[TBL] [Abstract][Full Text] [Related]
40. Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa.
James JF; Madray VM; Salame N; Hasan SB; White MS; Barron JR; Kirby J; Ingram JR; Orenstein LAV
Dermatology; 2023; 239(1):45-51. PubMed ID: 36108592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
